Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Divsa's coverage across Central America bridges Barentz' leading positions in North and South America
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
The system boasts features that help streamline processes in the SPD and OR and reduce the possibility of wet sets.
Successful proposals will secure fully funded postdoctoral research positions
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Subscribe To Our Newsletter & Stay Updated
